Sun Pharmaceutical Industries vs Cipla: Which Stock Should You Track
- July 31, 2026
- Posted by: Kunal Singla
- Category: News
Sun Pharmaceutical Industries vs Cipla: India’s largest pharmaceutical company by market cap vs a leading Indian pharmaceutical company with respiratory category leadership. Sun Pharmaceutical Indu…
Sun Pharmaceutical Industries vs Cipla is a comparison investors search for because the two companies represent genuinely different positions within Pharmaceuticals. This Sun Pharmaceutical Industries vs Cipla breakdown goes beyond generic labels and looks at real numbers: reach, products, the latest results each company has declared, and how each stock is positioned today. Understanding Sun Pharmaceutical Industries vs Cipla this way is more useful than a surface-level label, because it shows where each company actually stands rather than how it describes itself.
Sun Pharmaceutical Industries vs Cipla: Reach and Market Position
In the Sun Pharmaceutical Industries vs Cipla comparison, Sun Pharmaceutical Industries stands out for India’s largest drugmaker by market cap, with a growing specialty pharmaceuticals franchise alongside its generics business. This scale gives Sun Pharmaceutical Industries a distinct position within Pharmaceuticals that shapes how it competes.
Click Here – Get Free Investment Predictions
Cipla, on the other hand, is built around a leading Indian pharmaceutical company with a strong respiratory and India-business franchise, maintaining a net cash position of over Rs 9,000 crore. Comparing Sun Pharmaceutical Industries vs Cipla on reach alone shows two different growth strategies, not a single verdict.
Sun Pharmaceutical Industries vs Cipla: Key Products and Business Mix
Sun Pharmaceutical Industries’s business runs on generic drugs, specialty pharmaceuticals (including the Ilumya brand), and active pharmaceutical ingredients. This product mix is central to any Sun Pharmaceutical Industries vs Cipla comparison, since it explains where each company’s revenue actually comes from.
Cipla instead leans on respiratory therapies, generic drugs, oncology treatments, and One India branded formulations. The Sun Pharmaceutical Industries vs Cipla product comparison shows these are genuinely different businesses, not just different brand names in the same category.
Sun Pharmaceutical Industries vs Cipla: Latest Results
Looking at real numbers rather than claims, Sun Pharmaceutical Industries’s latest disclosed results show Q1 FY27 results were scheduled for July 31, 2026; analysts had projected around 11% topline growth with profit expected to decline 7-11% YoY on margin pressure from higher input costs. This is the clearest evidence available for the Sun Pharmaceutical Industries vs Cipla comparison on Sun Pharmaceutical Industries’s side.
Cipla’s latest disclosed results show Q1 FY27 net profit of Rs 785.55 crore, down 39.2% YoY, on revenue of Rs 7,119.28 crore, up 2.33%, with the decline driven by margin contraction and new labour-code-related costs even as India business revenue hit a record Rs 3,452 crore; FY26 revenue was a record Rs 28,000 crore. Weighing Sun Pharmaceutical Industries vs Cipla on actual results, rather than headline positioning, is what separates a useful comparison from a generic one.
Compare Sun Pharmaceutical Industries and Cipla Fundamentals on the Univest Screener
Sun Pharmaceutical Industries vs Cipla: Stock and Valuation
On the market side, Sun Pharmaceutical Industries is described as: Market cap around Rs 4,32,036 crore. Cipla is described as: Maintained a strong net cash position despite the profit decline. The Sun Pharmaceutical Industries vs Cipla valuation gap often reflects how the market is pricing each company’s growth and risk profile differently.
Sun Pharmaceutical Industries vs Cipla: Quick Comparison Table
| Parameter | Sun Pharmaceutical Industries | Cipla |
|---|---|---|
| Sector | Pharmaceuticals | Pharmaceuticals |
| Market position | India’s largest pharmaceutical company by market cap | a leading Indian pharmaceutical company with respiratory category leadership |
| Reach | India’s largest drugmaker by market cap, with a growing specialty pharmaceuticals franchis | a leading Indian pharmaceutical company with a strong respiratory and India-business franc |
| Latest results | Q1 FY27 results were scheduled for July 31, 2026; analysts had projected around 11% topline growth w | Q1 FY27 net profit of Rs 785.55 crore, down 39.2% YoY, on revenue of Rs 7,119.28 crore, up 2.33%, wi |
Conclusion
Sun Pharmaceutical Industries vs Cipla ultimately comes down to two companies solving similar problems in different ways. Sun Pharmaceutical Industries brings India’s largest pharmaceutical company by market cap, while Cipla brings a leading Indian pharmaceutical company with respiratory category leadership. Investors weighing Sun Pharmaceutical Industries vs Cipla should track both companies’ upcoming results and valuation gap rather than picking a side on reputation alone. This Sun Pharmaceutical Industries vs Cipla breakdown is a starting point, not a final verdict.
Download the Univest iOS App or Univest Android App to track Sun Pharmaceutical Industries and Cipla live price and get daily stock recommendations.
Disclaimer: Data and figures in this article are sourced from publicly available information, including company results filings and exchange data, and are current as of the time of writing. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the main difference between Sun Pharmaceutical Industries and Cipla?
Ans. The main difference in the Sun Pharmaceutical Industries vs Cipla comparison lies in scale and business mix. Sun Pharmaceutical Industries is built on India’s largest pharmaceutical company by market cap, while Cipla is positioned around a leading Indian pharmaceutical company with respiratory category leadership.
How do Sun Pharmaceutical Industries and Cipla’s latest results compare?
Ans. Comparing Sun Pharmaceutical Industries vs Cipla on latest disclosed results: Sun Pharmaceutical Industries reported Q1 FY27 results were scheduled for July 31, 2026; analysts had projected around 11% topline growth with profit expected to decline 7-11% YoY, while Cipla reported Q1 FY27 net profit of Rs 785.55 crore, down 39.2% YoY, on revenue of Rs 7,119.28 crore, up 2.33%, with the decline driven by margin contract.
What sector do Sun Pharmaceutical Industries and Cipla operate in?
Ans. Sun Pharmaceutical Industries operates in Pharmaceuticals and Cipla operates in Pharmaceuticals. Even where the sectors overlap, the Sun Pharmaceutical Industries vs Cipla comparison shows different product mixes and market positions.
Should I invest in Sun Pharmaceutical Industries or Cipla?
Ans. Both Sun Pharmaceutical Industries and Cipla have distinct strengths within their space. Investors comparing Sun Pharmaceutical Industries vs Cipla should review the latest quarterly results, valuation and their own risk profile, and consult a financial advisor before deciding.
What are the key products of Sun Pharmaceutical Industries?
Ans. Sun Pharmaceutical Industries’s key products and business lines include generic drugs, specialty pharmaceuticals (including the Ilumya brand), and active pharmaceutical ingredients.
What are the key products of Cipla?
Ans. Cipla’s key products and business lines include respiratory therapies, generic drugs, oncology treatments, and One India branded formulations.
How do Sun Pharmaceutical Industries and Cipla compare on market position?
Ans. On market position, Sun Pharmaceutical Industries holds India’s largest pharmaceutical company by market cap, while Cipla holds a leading Indian pharmaceutical company with respiratory category leadership. The Sun Pharmaceutical Industries vs Cipla comparison shows both companies lead in different ways rather than one being universally ahead.
